Site Navigation
General Information
Categories: biotechnology & health, nanotechnology
BSA 08-07: Carbon Nanotube-Based Drug Delivery Systems
BNL Reference Number: BSA 08-07
Patent Status: Application Number 20100021471 was published on January 28, 2010
Summary
Most drugs now in use require systemic exposure, i.e., the whole body is exposed, healthy or diseased. Many powerful drugs must be titrated carefully as they can damage healthy systems as well as diseased ones. In this carbon nanotube (NT) drug delivery system, two functional groups are attached to the NT: a recognition sequence that recognizes a diseased cell or organ, and a pro-drug destined for the cell. Once the recognition sequence allows the NT to enter the cell, the pro-drug is metabolized into its cytotoxic form to kill the diseased cell.
Description
A tumor-targeted drug carrier system contains single walled carbon nanotubes which are simultaneously functionalized with tumor cell receptors and with a prodrug that is activated to its cytotoxic formulation within the tumor cell.
Benefits
Carbon nanotube-assisted drug delivery systems offer efficient targeting and amplification of tumor-targeting due to an enhanced permeability and retention effect of the carbon nanotube which can be efficiently loaded with the drug.
Applications and Industries
The method can be used to develop functionalized carbon nanotube delivery system for diagnostics and therapeutic purposes.
Have Questions?
For more information about this technology, contact Kimberley Elcess, (631) 344-4151.
Tags: carbon nanotube, pro-drug, therapy
